Emergent BioSolutions Inc.
EBS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $469 | $346 | $264 | $518 |
| - Cash | $246 | $267 | $149 | $100 |
| + Debt | $663 | $668 | $666 | $664 |
| Enterprise Value | $887 | $746 | $781 | $1,082 |
| Revenue | $231 | $141 | $222 | $195 |
| % Growth | 64% | -36.6% | 14.1% | – |
| Gross Profit | $139 | $61 | $119 | $137 |
| % Margin | 60.3% | 43.1% | 53.7% | 70.1% |
| EBITDA | $96 | $24 | $75 | $21 |
| % Margin | 41.6% | 16.7% | 33.8% | 10.8% |
| Net Income | $51 | -$12 | $68 | -$31 |
| % Margin | 22.2% | -8.5% | 30.6% | -16.1% |
| EPS Diluted | 0.91 | -0.22 | 1.19 | -0.59 |
| % Growth | 513.6% | -118.5% | 301.7% | – |
| Operating Cash Flow | -$2 | $106 | -$11 | -$80 |
| Capital Expenditures | -$3 | -$3 | -$4 | -$2 |
| Free Cash Flow | -$6 | $104 | -$15 | -$82 |